A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

City of Hope, Duarte, California, United States

City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States

University of California San Francisco, San Francisco, California, United States

Colorado Blood Cancer Institute, Denver, Colorado, United States

Icahn School of Medicine at Mt. Sinai, New York, New York, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Levine Cancer Institute, Charlotte, North Carolina, United States

University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States

MD Anderson Cancer Center, Houston, Texas, United States

UZ Antwerpen, Edegem, Belgium

UZ Gent, Ghent, Belgium

CHU de Liege, Liège, Belgium

CHU Nantes, Nantes, France

CHU Lyon Sud, Pierre-Bénite, France

Chu Rennes Hopital Pontchaillou, Rennes, France

Institut Claudius Regaud, Toulouse, France

Japanese Red Cross Medical Center, Shibuya City, Japan

Osaka University Hospital, Suita-shi, Japan

The Cancer Institute Hospital of JFCR, Tokyo, Japan

VUMC Amsterdam, Amsterdam, Netherlands

Universitair Medisch Centrum Groningen, Groningen, Netherlands

UMC Utrecht, Utrecht, Netherlands

Hosp. Univ. Germans Trias I Pujol, Badalona, Spain

Hosp Clinic de Barcelona, Barcelona, Spain

Hosp Univ Fund Jimenez Diaz, Madrid, Spain

Clinica Univ. de Navarra, Pamplona, Spain

Hosp Clinico Univ de Salamanca, Salamanca, Spain

University College Hospital, London, United Kingdom

Royal Marsden Hospital, Sutton, United Kingdom